HIV prevention drug to be made affordable in Nigeria, 119 countries Gilead Sciences has announced plans to make cheaper versions of its revolutionary HIV prevention drug, lenacapavir, available in 120 low and middle-income countries, including Nigeria. Lenacapavir, a long-acting HIV treatment given as a twice-yearly injection, has demonstrated significant success in preventing HIV infections during clinical trials. In South Africa and Uganda, lenacapavir stopped new infections among girls and women, while a separate trial involving men from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US showed nearly complete protection against...